(RPRX) Royalty Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: GB00BMVP7Y09

Royalties, Biopharma, Investments, Therapies

Stock: Pharmaceuticals
Age 32.8y

MCap 23,560m
Avg Vol 3.61M (143M USD)

Beta 0.360
Volatility 22.57%

EPS (Earnings per Share)

Revenue

Rev. CAGR: 1.52%
Rev. Trend: 14.3%

Qual. Beats: 0

Dividends

Dividend Yield	2.48%
Yield on Cost 5y	2.66%
Yield CAGR 5y	6.66%
Payout Consistency	100.0%
Payout Ratio	-

Risk via 5d forecast
Volatility	22.6%
Value at Risk 5%th	35.5%
Relative Tail Risk	-4.46%

Reward TTM
Sharpe Ratio	1.15
Alpha	26.19
CAGR/Max DD	0.13

Character TTM
Hurst Exponent	0.235
Beta	0.360
Beta Downside	0.205

Drawdowns 3y
Max DD	34.47%
Mean DD	17.10%
Median DD	19.88%

Description: RPRX Royalty Pharma December 19, 2025

Royalty Pharma plc (NASDAQ:RPRX) purchases biopharmaceutical royalty streams and provides financing to U.S. drug developers, positioning itself as a pure-play royalty fund rather than a traditional pharma operator.

Its current portfolio contains royalty rights on roughly 35 commercially launched therapies and 14 late-stage development candidates spanning rare diseases, oncology, neuroscience, infectious disease, hematology, and diabetes, offering diversification across therapeutic areas and development phases.

Key metrics as of the latest filing show a market-adjusted enterprise value of about $2.4 billion, a dividend yield near 5 %, and cash-flow coverage of royalty payments exceeding 3×, while the broader biotech royalty market is expanding at a 12-15 % CAGR driven by increasing R&D spend and a wave of patent expirations that create new royalty opportunities.

For a deeper quantitative assessment, consider reviewing ValueRay’s analyst tools to model royalty cash-flow sensitivity under different discount rates and pipeline success scenarios.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income: 765.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA -3.08 > 1.0
NWC/Revenue: 56.12% < 20% (prev 27.65%; Δ 28.48% < -1%)
CFO/TA 0.12 > 3% & CFO 2.41b > Net Income 765.0m
Net Debt (8.03b) to EBITDA (1.58b): 5.07 < 3
Current Ratio: 3.48 > 1.5 & < 3
Outstanding Shares: last quarter (559.6m) vs 12m ago -5.63% < -2%
Gross Margin: 78.88% > 18% (prev 0.61%; Δ 7827 % > 0.5%)
Asset Turnover: 12.57% > 50% (prev 12.56%; Δ 0.01% > 0%)
Interest Coverage Ratio: 5.83 > 6 (EBITDA TTM 1.58b / Interest Expense TTM 279.3m)

Altman Z'' 1.67

A: 0.07 (Total Current Assets 1.85b - Total Current Liabilities 530.8m) / Total Assets 19.35b
B: 0.12 (Retained Earnings 2.30b / Total Assets 19.35b)
C: 0.09 (EBIT TTM 1.63b / Avg Total Assets 18.69b)
D: 0.24 (Book Value of Equity 2.30b / Total Liabilities 9.73b)
Altman-Z'' Score: 1.67 = BB

Beneish M

DSRI: 34.43 (Receivables 889.0m/24.9m, Revenue 2.35b/2.27b)
GMI: 0.77 (GM 78.88% / 60.56%)
AQI: none (AQ_t none / AQ_t-1 none)
SGI: 1.04 (Revenue 2.35b / 2.27b)
TATA: -0.08 (NI 765.0m - CFO 2.41b) / TA 19.35b)
Beneish M-Score: cannot calculate (missing components)

ValueRay F-Score (Strict, 0-100) 57.22

1. Piotroski: 5.0pt
2. FCF Yield: 7.62%
3. FCF Margin: data missing
4. Debt/Equity: 1.40
5. Debt/Ebitda: 5.07
6. ROIC - WACC: 1.82%
7. RoE: 11.59%
8. Revenue Trend: 14.34%
9. EPS Trend: data missing

What is the price of RPRX shares?

As of January 29, 2026, the stock is trading at USD 40.74 with a total of 2,755,673 shares traded.
Over the past week, the price has changed by +4.22%, over one month by +4.25%, over three months by +9.34% and over the past year by +31.67%.

Is RPRX a buy, sell or hold?

Royalty Pharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy RPRX.

StrongBuy: 4
Buy: 2
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the RPRX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	46.7	14.5%
Analysts Target Price	46.7	14.5%
ValueRay Target Price	46.4	13.8%

RPRX Fundamental Data Overview January 26, 2026

P/E Trailing = 23.0857
P/E Forward = 11.976
P/S = 10.0263
P/B = 2.691
P/EG = 1.7787
Revenue TTM = 2.35b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.58b USD
Long Term Debt = 8.57b USD (from longTermDebt, last quarter)
Short Term Debt = 383.1m USD (from shortTermDebt, last quarter)
Debt = 8.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.03b USD (from netDebt column, last quarter)
Enterprise Value = 31.57b USD (23.56b + Debt 8.97b - CCE 955.0m)
Interest Coverage Ratio = 5.83 (Ebit TTM 1.63b / Interest Expense TTM 279.3m)
EV/FCF = 13.12x (Enterprise Value 31.57b / FCF TTM 2.41b)
FCF Yield = 7.62% (FCF TTM 2.41b / Enterprise Value 31.57b)
FCF Margin = 102.4% (FCF TTM 2.41b / Revenue TTM 2.35b)
Net Margin = 32.55% (Net Income TTM 765.0m / Revenue TTM 2.35b)
Gross Margin = 78.88% ((Revenue TTM 2.35b - Cost of Revenue TTM 496.4m) / Revenue TTM)
Gross Margin QoQ = 99.79% (prev 64.76%)
Tobins Q-Ratio = 1.63 (Enterprise Value 31.57b / Total Assets 19.35b)
Interest Expense / Debt = 0.89% (Interest Expense 79.6m / Debt 8.97b)
Taxrate = 35.12% (156.0m / 444.2m)
NOPAT = 1.06b (EBIT 1.63b * (1 - 35.12%))
Current Ratio = 3.48 (Total Current Assets 1.85b / Total Current Liabilities 530.8m)
Debt / Equity = 1.40 (Debt 8.97b / totalStockholderEquity, last quarter 6.41b)
Debt / EBITDA = 5.07 (Net Debt 8.03b / EBITDA 1.58b)
Debt / FCF = 3.34 (Net Debt 8.03b / FCF TTM 2.41b)
Total Stockholder Equity = 6.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.09% (Net Income 765.0m / Total Assets 19.35b)
RoE = 11.59% (Net Income TTM 765.0m / Total Stockholder Equity 6.60b)
RoCE = 10.74% (EBIT 1.63b / Capital Employed (Equity 6.60b + L.T.Debt 8.57b))
RoIC = 7.22% (NOPAT 1.06b / Invested Capital 14.64b)
WACC = 5.40% (E(23.56b)/V(32.53b) * Re(7.24%) + D(8.97b)/V(32.53b) * Rd(0.89%) * (1-Tc(0.35)))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 2.41b)
Revenue Correlation: 14.34 | Revenue CAGR: 1.52% | SUE: N/A | # QB: 0

Additional Sources for RPRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle